211230-35-2

Basic information

• Product Name: 4-(4-MethoxybenzylaMino)-5-ethoxycarbonyl-2-MethylthiopyriMidine
• Synonyms: 4-(4-MethoxybenzylaMino)-5-ethoxycarbonyl-2-MethylthiopyriMidine
• CAS NO: 211230-35-2
• Molecular Formula: C₁₆H₁₉N₃O₃S
• Molecular Weight: 333.40536
• EINECS: -0
• Mol File: 211230-35-2.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 493.6±35.0 °C(Predicted)
• Appearance: /
• Density: 1.26±0.1 g/cm3(Predicted)
• Storage Temp.: 2-8°C(protect from light)
• PKA: 2.81±0.10(Predicted)
• CAS DataBase Reference: 4-(4-MethoxybenzylaMino)-5-ethoxycarbonyl-2-MethylthiopyriMidine(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(4-MethoxybenzylaMino)-5-ethoxycarbonyl-2-MethylthiopyriMidine(211230-35-2)
• EPA Substance Registry System: 4-(4-MethoxybenzylaMino)-5-ethoxycarbonyl-2-MethylthiopyriMidine(211230-35-2)

Safety Data

• Hazardous Substances Data: 211230-35-2(Hazardous Substances Data)

Usage

Description

4-(4-Methoxybenzylamino)-5-ethoxycarbonyl-2-methylthiopyrimidine is a pyrimidine derivative characterized by the presence of a 4-methoxybenzylamine group, an ethoxycarbonyl group, and a methylthio substituent. 4-(4-MethoxybenzylaMino)-5-ethoxycarbonyl-2-MethylthiopyriMidine exhibits unique structural features that make it a promising candidate for various applications, particularly in the pharmaceutical industry.

Uses

Used in Pharmaceutical Industry:
4-(4-Methoxybenzylamino)-5-ethoxycarbonyl-2-methylthiopyrimidine is used as a key intermediate in the synthesis of pyrimidine derivatives, which have potential therapeutic applications in the treatment of metabolic bone diseases. These pyrimidine derivatives may help regulate bone metabolism and improve bone health by targeting specific biological pathways involved in bone formation and resorption.
In the preparation of pyrimidine derivatives for the treatment of metabolic bone disease, 4-(4-Methoxybenzylamino)-5-ethoxycarbonyl-2-methylthiopyrimidine plays a crucial role as a building block. Its unique structural features allow for the development of novel therapeutic agents that can address the unmet medical needs of patients suffering from metabolic bone disorders, such as osteoporosis and osteogenesis imperfecta. By incorporating this compound into the molecular design of new drugs, researchers can potentially enhance the efficacy, selectivity, and safety of treatments for these conditions.

Upstream product

• 53554-29-3 ethyl 4-hydroxy-2-(methylthio)pyrimidine-5-carboxylate 
• 87-13-8 diethyl 2-ethoxymethylenemalonate 
• 5909-24-0 4-chloro-2-methanesulfanylpyrimidine-5-carboxylic acid ethyl ester 
• 2393-23-9 4-methoxy-benzylamine 

Downstream Products

• 211230-36-3 [4-(4-methoxybenzylamino)-2-methanesulfanyl-pyrimidin-5-yl]-methanol 

Relevant articles and documents

Identification, synthesis and characterization of avanafil process impurities and determination by UPLC

Avanafil is a phosphodiesterase type 5 inhibitor which is used to treat erectile dysfunction in men. The process-related impurities of avanafil were investigated, and four kinds of impurities in several laboratory batches with a content of 0.29-1.63% were detected by the newly developed gradient ultra-high performance liquid chromatography (UPLC). Based on the synthesis route and UPLC-MS research, the impurities are inferred as Imp-A, Imp-B, Imp-C and Imp-D. The structures of the impurities were inferred from LC-MS studies and confirmed by synthesis, followed by spectroscopic characterization such as NMR and mass spectrometry. Especially, the synthesis of Imp-D is firstly reported. The drug-related substances can be separated well by efficient and selective ultra-high performance liquid chromatography on a Waters ACQUITY HSS C18 (50 × 2.1 mm, particle size 1.8 μm) column at 35 °C, with the mobile phase consisting of ammonium formate (20 mM) and acetonitrile, and the detection at 239 nm with a DAD detector. The method was validated in terms of specificity, linearity, precision, accuracy and sensitivity, and satisfactory results were obtained. The results indicated this developed UPLC method for avanafil and the proposed synthesis mechanism can be used for quality control purposes as required by regulatory agencies to ensure the safety and efficacy of the product.

Pyridopyrimidinone derivatives for treatment of neurodegenerative disease

This invention provides pyridopyrimidines and 4-aminopyrimidines that are useful for treating cell proliferatives disorders, such as cancer and restenosis. We have now discovered a group of 7,8-dihydro-2 (amino and thio)pyrido[2,3-d]pyrimidines and 2,4-di